Encephalopathy News and Research

RSS

New insights into specific types of brain abnormalities

Postmortem analysis of the brains of ten professional athletes with chronic traumatic encephalopathy (CTE) provides new insights into the specific types of brain abnormalities associated with this diagnosis, reports a study in the July issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

13 Jul 2011

FDA approves BOOSTRIX to prevent tetanus, diphtheria and pertussis in older people

The U.S. Food and Drug Administration (FDA) has approved BOOSTRIX for use in adults 65 years of age and older for active booster immunization against tetanus, diphtheria and pertussis.

11 Jul 2011

Researchers identify altered expression of endogenous retroviruses in BSE-infected macaques

Prion diseases such as Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy (BSE) in cattle are transmissible neurodegenerative diseases linked to the aggregation of the prion protein in the central nervous system.

1 Jul 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

Travel, hunting, and venison consumption linked to prion diseases

Researchers from the Centers for Disease Control and Prevention have examined the potential for human exposure to prion diseases, looking at hunting, venison consumption, and travel to areas in which prion diseases have been reported in animals.

23 May 2011

NAA calls for immediate Congressional hearings and scientific investigation into autism-vaccine link

Despite numerous studies cited repeatedly by federal officials as proof that vaccines do not cause autism, a new study released today in the Pace Environmental Law Review revealed that over the last two decades, the National Vaccine Injury Compensation Program has been quietly compensating dozens of vaccine injury cases involving a child with autism.

11 May 2011

CSEW fails to protect public health by refusing to take part in variant Creutzfeldt-Jakob disease study

The creation of a post-mortem tissue archive for a study of the human form of mad cow disease failed because of a "misguided" refusal by coroners to participate.

9 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Experts to teach athletic trainers, medical providers on sports head injuries

Top experts from around the country will be at the University of North Carolina at Chapel Hill later this week to teach athletic trainers and medical providers how to prevent deaths and serious injuries among high school and college athletes.

28 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Cognitive impairment may not be fully reversible in patients with liver disease: Study

There are potential legal ramifications for physicians of patients who drive with cognitive impairment, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

19 Mar 2011

New research may shed light on possible treatments for prion diseases

New research by Chongsuk Ryou, researcher at the UK Sanders-Brown Center on Aging and professor of microbiology, immunology and molecular genetics in the UK College of Medicine, may shed light on possible treatments for prion diseases.

15 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Baby frozen to correct brain damage at birth makes full recovery

Baby Ella was born starved of oxygen but doctors cooled her body for three days to reduce brain damage. She made a complete recovery. After birth Ella was wrapped in a special blanket filled with fluid which cooled her whole body down from the normal 37°c to 33.5°c by doctors at Addenbrooke’s Hospital in Cambridge.

3 Mar 2011

New study examines boxing injuries among children and adolescents from 1990 to 2008

The risk and nature of injury in the sport of boxing has generated a great deal of controversy in the medical community, especially in relation to youth boxing. A new study, conducted by researchers in the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital, examined boxing injuries among participants 6 years of age and older from 1990 to 2008.

3 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

25 Feb 2011

Blood test for screening mad cow disease to come soon: Study

UK scientists have developed a new blood test that can diagnose cases of variant Creutzfeldt-Jakob Disease (vCJD), a rare, fatal brain disease caused by proteins known as prions. These prions are also responsible for the mad cow disease, or bovine spongiform encephalopathy (BSE). This test could in near future be used to identify contaminated blood and prevent transmission of the disease during blood transfusions, the researchers said.

6 Feb 2011